What is HRD Testing?
- A genetic test that examines the ability of cancer cells to repair DNA damage.
- It identifies the likelihood of success for PARP inhibitor treatments.
- A critical tool in personalized oncology and precision medicine.
Book HRD Testing in Saudi Arabia | Lahalak Medical Platform
HRD testing identifies the best treatment for ovarian and breast cancers by assessing genomic instability. It predicts response to PARP inhibitors, enabling personalized and highly effective oncology care.
Scientific name: Homologous Recombination Deficiency (HRD) Testing
An advanced laboratory test analyzing genomic instability in tumors. It identifies patients likely to benefit from targeted therapies, specifically PARP inhibitors, in advanced ovarian and breast cancer cases.
Service type
Genetic Laboratory Test
Duration
15-20 minutes
Fasting
Fasting is not required
Included Services
- Blood sample or biopsy collection
- Genomic Instability Score (GIS) analysis
- Detailed medical result report
Medical Service Information
Why is this test performed?
- To predict response to chemotherapy and targeted therapy in ovarian cancer.
- To assess treatment options for advanced breast cancer patients.
- To optimize treatment outcomes and avoid unnecessary side effects.
Who should get this test?
- Patients with advanced-stage ovarian cancer.
- Breast cancer patients with a strong family history of the disease.
- Patients being considered for PARP inhibitor therapy.
Conditions & Notices
- Previous oncology medical reports must be provided
- Oncologist consultation is recommended before the test
Medical services you might also like
